# EDGAR Filing Document

**Accession Number:** 0001783010
**File Stem:** 0001140361-23-013251
**Filing Date:** 2023-3
**Character Count:** 15228
**Document Hash:** 8825c5bb24e9267b9ee9ff97ec1c3558
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-013251.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0001140361-23-013251

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230322

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Amryt Pharma plc
- **CENTRAL INDEX KEY:** 0001783010
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39365
- **FILM NUMBER:** 23754618

**BUSINESS ADDRESS:**
- **STREET 1:** DEPT 920A, 196 HIGH ROAD
- **STREET 2:** WOOD GREEN
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** N22 8HH
- **BUSINESS PHONE:** 353-1-518-0200

**MAIL ADDRESS:**
- **STREET 1:** 45 MESPIL ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** D04 W2F1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Amryt Pharma Holdings Ltd
- **DATE OF NAME CHANGE:** 20190719

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 6-K

#### Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

#### under the Securities Exchange Act of 1934

#### For the month of March, 2023

**Commission File Number:**001-39365

## Amryt Pharma PLC
(Translation of registrant's name into English)

#### Dept 920a 196 High Road, Wood Green,

#### London, United Kingdom, N22 8HH
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):<u> </u>☐

<br> Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

#### Results of Amryt Shareholder Meetings.

On March 22, 2023, Amryt Pharma Plc (the "<u>Company</u>") held a meeting of shareholders convened with the permission of the High Court of Justice of England and Wales (the "<u>Court</u>" and, such meeting, the "<u>Court Meeting</u>") and a general meeting of shareholders (the "<u>General Meeting</u>" and together with the Court Meeting, the "<u>Shareholder Meetings</u>"), in each case in connection with the previously announced transaction whereby Chiesi Farmaceutici S.p.A., an Italian società per azioni ("<u>Chiesi</u>"), will acquire the entire issued and to be issued share capital of the Company (the "<u>Transaction</u>") pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "<u>Scheme of Arrangement</u>"). The Company published a scheme circular regarding the Transaction on February 16, 2023 (the "<u>Scheme Circular</u>").

As of 6:00 p.m. (London time) on March 20, 2023, the voting record time for the Shareholder Meetings (the "<u>Voting Record Time</u>"), the Company's issued share capital consisted of 320,669,417 ordinary shares carrying one vote each. 244,113,996 ordinary shares of the Company were voted by shareholders present in person or by proxy at the Court Meeting. 243,891,202 ordinary shares of the Company were voted by shareholders present in person or by proxy at the General Meeting. All votes at both the Court Meeting and the General Meeting were conducted on a poll.

The final results of voting on each of the items submitted to a vote of the Company's shareholders at the Court Meeting and the General Meeting are set forth below.

The consummation of the Transaction remains subject to closing conditions, including the sanction of the Scheme of Arrangement by the Court.

#### Court Meeting

#### Scheme Proposal: to approve the Scheme of Arrangement.

The Company's shareholders approved the Scheme Proposal with the following results:

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **% OF SCHEME**<br> **SHARES FOR** | **AGAINST** | **% OF SCHEME**<br> **SHARES AGAINST** |
| **243833323**  | **99.89%**  | **280673**  | **0.11%**  |

---

Of the 112 record shareholders voting on the proposal, 107 record shareholders or 95.54% of those voting voted in favor of the proposal (constituting a majority in number of record voters voting in person or by proxy who together held in excess of 75% in value of the shares represented) and 5 record shareholders or 4.46% of those voting voted against the proposal.

#### General Meeting

***Scheme Implementation Proposal: to (i) authorize the Company's Board of Directors to take all action necessary or appropriate for carrying the Scheme of Arrangement into effect and (ii) make certain amendments to the articles of association of the Company in order to facilitate the Transaction, including provisions to ensure that any of the Company's ordinary shares that are issued at or after the Voting Record Time will either be subject to the terms of the Scheme of Arrangement or will be acquired by Chiesi on the same terms as under the Scheme of Arrangement.***

The Company's shareholders approved the Scheme Implementation Proposal with the following results:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **FOR** | **% OF SCHEME**<br> **SHARES FOR** | **AGAINST** | **% OF SCHEME**<br> **SHARES AGAINST** | **WITHHELD** |
| **243827890**  | **99.97%**  | **63312**  | **0.03%**  | **14990**  |

---

Further information regarding each of the foregoing proposals is set forth in the Scheme Circular.

------

#### Results Announcement Press Release

On March 22, 2023, the Company issued a press release announcing the results of the Shareholder Meetings, which also discloses that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in respect of the Transaction has expired. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

------

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Amryt Pharma Plc | Amryt Pharma Plc |
|  | By: | /s/ Rory Nealon |
|  | Name: | Rory Nealon |
|  | Title: | Chief Financial Officer |
| Date: March 22, 2023 |  |  |

---

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit**<br> **<u>Number</u>** | **<u>Description</u>** |
| [99.1](brhc10050141_ex99-1.htm) | Press Release of the Company, dated March 22, 2023. |

---

4<br>

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

**** <br> ![](image00001.jpg)

#### <br>

#### Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

*Transaction Expected to Close in Q2 2023*

**Dublin, Ireland, March 22, 2023** Amryt Pharma Plc ("Amryt") (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today's shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi Farmaceutici S.p.A., (the "Transaction") were duly passed. The full text of each resolution was included in the notice of the shareholder meetings posted to shareholders on February 16, 2023, and is available on the Company's website <u>www.amrytpharma.com/investors</u>.

The waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Transaction has expired. The closing of the Transaction remains subject to certain other regulatory approvals and the satisfaction or waiver of certain other customary closing conditions, including obtaining the sanction of the High Court of Justice of England and Wales. Amryt expects the Transaction will close in the second quarter of 2023.

#### About Amryt
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. For more information on Amryt, including products, please visit www.amrytpharma.com.

#### Forward-Looking Statements
This announcement contains forward-looking statements regarding Amryt, including, but not limited to, statements related to the proposed acquisition of Amryt and the anticipated timing thereof, and other statements that are not historical facts. You can generally identify forward-looking statements by the use of forward-looking terminology such as the words: "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the companies' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties, many of which are beyond Amryt's control.

------

Actual timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Chiesi's and Amryt's ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals, the sanction of the Court and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive Transaction agreement relating to the proposed acquisition; risks related to diverting the attention of Chiesi's and Amryt's management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant Transaction costs and/or unknown or inestimable liabilities; the risk of shareholder litigation in connection with the proposed Transaction, including resulting expense or delay; the risk that Amryt's business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; Chiesi's ability to fund the cash consideration for the acquisition; the risks that the conditions to payment for the contingent value rights issued in connection with the Transaction will not be met or that such contingent value rights will otherwise never delivery any value to Amryt shareholders; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Amryt ADSs or ordinary shares; regulatory initiatives and changes in tax laws; market volatility; and other risks and uncertainties affecting Amryt, including those described from time to time under the caption "Risk Factors" and elsewhere in Amryt's Securities and Exchange Commission ("SEC") filings and reports, including the Scheme Circular published by Amryt in connection with the Transaction and furnished to the SEC on Form 6-K, Amryt's Annual Report on Form 20-F for the year ended December 31, 2021 and any filings on Form 6-K which Amryt has filed or may file in the future. Moreover, other risks and uncertainties of which Amryt is not currently aware may also affect Amryt's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance.

The forward-looking statements made in this announcement are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events as at such dates, even if they are subsequently made available by Amryt on its website or otherwise. Amryt does not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made other than to the extent required by applicable law.

#### Important Additional Information and Where to Find It
This announcement is not a substitute for the Scheme Circular or any other document that may be filed or furnished by Amryt with the SEC. Investors and security holders are urged to carefully read the entire Scheme Circular (which includes an explanatory statement in respect of the Scheme of Arrangement in accordance with the requirements of the U.K. Companies Act 2006 and is available to view at https://amrytpharma.com/investors/) and other relevant documents as and when they become available because they will contain important information.

Neither this announcement nor any copy of it may be taken or transmitted directly or indirectly into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. Any failure to comply with this restriction may constitute a violation of such laws or regulations. Persons in possession of this announcement or other information referred to herein should inform themselves about, and observe, any restrictions in such laws or regulations.

------

This announcement has been prepared for the purpose of complying with the applicable law and regulation of the United Kingdom and the United States and information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of jurisdictions outside the United Kingdom or the United States.

#### No Offer or Solicitation
This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in respect of such actions in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

#### Amryt Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com

Tim McCarthy, LifeSci Advisors, LLC, +1 (917) 679 9282, tim@lifesciadvisors.com

------